Genelux Corp

Genelux Corp operates with a market capitalization of $136.31 million and a price-to-book ratio of 3.62, indicating a premium valuation relative to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, reflecting a conservative capital structure. Its current ratio of 6.01 suggests strong short-term liquidity, with current assets significantly outpacing current liabilities.

Profitability metrics are negative, with a return on equity of -17.46% and a return on assets of -14.56%, indicating that the company is not generating returns for shareholders or asset holders. Operating and net losses of $6.89 million and $6.58 million, respectively, underscore the company's ongoing financial challenges.

Geographically and segment-wise, Genelux does not disclose specific revenue concentrations in its latest financials, but as a development-stage biotechnology firm, its operations are likely centered in the United States. The company's revenue remains at $0.00, consistent with its pre-revenue status.

Looking ahead, Genelux is expected to continue incurring losses as it advances its pipeline. The company's operating cash flow of -$11.18 million and free cash flow of -$6.77 million highlight the need for continued capital infusions. Analysts have assigned a mean price target of $17.50, with a median of $16.00, suggesting a potential upside from the current market price of $3.04.

Risk factors include the company's lack of revenue and ongoing losses, which could necessitate further equity or debt financing. However, the risk assessment indicates low dilution and liquidity risks, with no immediate filing-based flags detected. The company's capital expenditure of -$258,000 is minimal, suggesting limited near-term infrastructure or facility investments.

Recent events include the continued development of obiltox, with no major regulatory or clinical setbacks reported in the latest filings. The company's focus remains on advancing its pipeline through clinical trials, with no recent material events impacting its financial position.

Analysts project 501% upside to a mean price target of $17.50, significantly above the current market price of $2.91.

The company maintains a low leverage band with a debt-to-equity ratio of 0.65 and a healthy current ratio of 2.43.

Cash conversion metrics are rated best-in-class at 1.7, substantially exceeding the cohort median of 0.87.

Risk flags for dilution, liquidity, and credit are all assessed as low, suggesting a stable near-term financial profile.

Net losses widened to $32.1 million in fiscal 2026, reflecting a 49% increase in losses compared to the prior period.

Free cash flow deteriorated to -$33.0 million in fiscal 2026, marking a 52% increase in cash burn year-over-year.

Operating income losses expanded to $33.2 million in fiscal 2026, up 56.2% from the previous fiscal year.

Return on invested capital stands at -18.3%, indicating significant value destruction relative to capital employed.

Revenue $0.00; Operating income −17,3% YoY.

• ▍Revenue $0.00
• ▍Operating income −17,3% YoY
• ▍Net income −19,2% YoY
• ▍Free cash flow −31,9% YoY

Revenue $0.00; Operating income −18,1% YoY.

• ▍Revenue $0.00
• ▍Operating income −18,1% YoY
• ▍Net income −22,9% YoY
• ▍Free cash flow −30,6% YoY

Revenue $0.00; Operating income −13,1% YoY.

• ▍Revenue $0.00
• ▍Operating income −13,1% YoY
• ▍Net income −13,4% YoY
• ▍Free cash flow −11,0% YoY

Revenue $0.00; Operating income -$7.8M.

• ▍Revenue $0.00
• ▍Operating income -$7.8M

Revenue $0.00; Operating income -$9.4M.

• ▍Revenue $0.00
• ▍Operating income -$9.4M

Operating income -$6.9M.

• ▍Operating income -$6.9M

Revenue $0.00; Operating income -$6.9M.

• ▍Revenue $0.00
• ▍Operating income -$6.9M

Revenue $8.0k, 0,0% YoY; Operating income −6,0% YoY.

• ▍Revenue $8.0k, 0,0% YoY
• ▍Operating income −6,0% YoY
• ▍Net income −7,6% YoY
• ▍Free cash flow −9,9% YoY
• ▍Net margin -401812.5%

Revenue $8.0k, −95,3% YoY; Operating income −27,5% YoY.

• ▍Revenue $8.0k, −95,3% YoY
• ▍Operating income −27,5% YoY
• ▍Net income −5,6% YoY
• ▍Free cash flow −4,1% YoY
• ▍Net margin -373362.5%

Revenue $170.0k, −98,5% YoY; Operating income −810,2% YoY.

• ▍Revenue $170.0k, −98,5% YoY
• ▍Operating income −810,2% YoY
• ▍Net income −443,4% YoY
• ▍Free cash flow −512,9% YoY
• ▍Net margin -16645.3%

Revenue $11.1M; Operating income +81,5% YoY.

• ▍Revenue $11.1M
• ▍Operating income +81,5% YoY
• ▍Net income +68,2% YoY
• ▍Free cash flow +70,3% YoY
• ▍Net margin -47.0%